Key Details
Price
$15.02Last Dividend
$0.19Annual ROE
6.87%Beta
0.56Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Sept 28, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
Mar 18, 1999Next split:
N/ARecent split:
Apr 17, 2007Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Despite recent underperformance, FONAR remains a value play with minimal debt, positive profitability, and attractive valuation multiples, particularly a P/B ratio of 0.61. Q1-Fiscal 2025 earnings showed a decline, but FONAR's book value continues to grow, driven by strategic investments in high-field MRI scanners and new locations. Risks include market punishment for near-term growth rates and low trading volume, but downside risk is limited due to strong financials and shareholder-friendly trends.
FONAR's fiscal first-quarter earnings reveals a decline in revenues and income, driven by decreased patient fees and rising costs, while MRI scan volume sees modest growth.
Total MRI scan volume at the HMCA-managed sites increased 11% to 209,327 scans for the fiscal year ending June 30, 2024 as compared to the prior year. Cash and Cash Equivalents increased 10% to $56.3 million at June 30, 2024 versus the previous fiscal year.
FONAR Corporation showed encouraging growth trends in revenues and earnings, leading to a 'Buy' rating last year. Recent technical trends suggest a potential long-term change in the stock trend, supported by strong near-term growth rates and a favorable valuation. Forward-looking fundamentals, including the adoption of SwiftMR, indicate potential for continued growth and profitability for FONR shareholders.
Discover why Zacks rates FONAR Corporation as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore FONR's strategic expansion, financial health and market positioning for growth in the MRI diagnostic services space.
The company specializes in overseeing diagnostic imaging centers, and it experiences steady and consistent revenue growth with decent profit margins. I believe that the second quarter results of fiscal year 2024 were impressive, with a 4.7% increase in revenues to $25.4 million and a 68.4% rise in attributable net income to $3.8 million. Fonar's market capitalization has dropped by more than 20% in the last month, presenting a favorable chance for investment.
FONAR Corporation's shares have declined 8.2% since I last wrote about it, while the S&P 500 gained 10.9%. The company's recent financial results show flatlined revenue and increased costs. Despite the weak performance, FONAR has a strong capital structure and the shares are objectively cheap, making it a potentially good investment. Patience is required in my view.
FAQ
- What is the primary business of FONAR?
- What is the ticker symbol for FONAR?
- Does FONAR pay dividends?
- What sector is FONAR in?
- What industry is FONAR in?
- What country is FONAR based in?
- When did FONAR go public?
- Is FONAR in the S&P 500?
- Is FONAR in the NASDAQ 100?
- Is FONAR in the Dow Jones?
- When was FONAR's last earnings report?
- When does FONAR report earnings?